Renal sympathetic denervation

Global Renal Denervation Technologies Market to Reach $745.7 Million by 2026

Retrieved on: 
Tuesday, August 3, 2021
Interventional radiology, Hypertension, Renal sympathetic denervation, Denervation, Medicine, Clinical medicine, Medical specialties

SAN FRANCISCO, Aug. 3, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Renal Denervation Technologies - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, Aug. 3, 2021 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Renal Denervation Technologies - Global Market Trajectory & Analytics" .
  • Amid the COVID-19 crisis, the global market for Renal Denervation Technologies estimated at US$113.3 Million in the year 2020, is projected to reach a revised size of US$745.7 Million by 2026, growing at a CAGR of 37.3% over the analysis period.
  • This segment currently accounts for a 22.4% share of the global Renal Denervation Technologies market.
  • The U.S. Market is Estimated at $35.8 Million in 2021, While China is Forecast to Reach $49.5 Million by 2026
    The Renal Denervation Technologies market in the U.S. is estimated at US$35.8 Million in the year 2021.

Late Breaking Data at EuroPCR Demonstrates Long-Term Benefits of Medtronic Radiofrequency Renal Denervation in Real-World Hypertensive Patients

Retrieved on: 
Tuesday, May 18, 2021
Interventional radiology, Hypertension, Medical specialties, Renal sympathetic denervation, Medicine, Clinical medicine, Denervation

Patients were treated with the Symplicity Renal Denervation System utilizing the single electrode Symplicity Catheter or the Symplicity Spyral Multi-Electrode Catheter, and their outcomes were analyzed up to three years post procedure.

Key Points: 
  • Patients were treated with the Symplicity Renal Denervation System utilizing the single electrode Symplicity Catheter or the Symplicity Spyral Multi-Electrode Catheter, and their outcomes were analyzed up to three years post procedure.
  • They found a consistent benefit of RDN in patients with versus without diabetes, chronic kidney disease, or patients who were 65 years and above.
  • "With this new analysis, we can now help patients continue to see the real-world benefits of renal denervation.
  • This new phase of patient data collection aims to enroll an additional 2,000 patients suffering from uncontrolled hypertension, who will be treated with the Medtronic Symplicity Spyral Multi-Electrode Renal Denervation Catheter.

Global Renal Denervation Devices Market (2020 to 2025) - Growth, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 27, 2021
Medical devices, Health, Hypertension, Interventional radiology, Medical specialties, Renal sympathetic denervation, Branches of biology, Medicine, Denervation, Kidney, Kidney diseases, Rare diseases

The "Renal Denervation Devices Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Renal Denervation Devices Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The major factors responsible for the growth of the renal denervation devices market include the rising prevalence of hypertension and the long-lasting effect of the procedure.
  • High blood pressure had been the primary contributing cause of death for more than 410,000 Americans, in 2014.
  • Thus, owing to all of the aforementioned factors, the market studied is expected to witness high growth, in the coming years.

ReCor Medical Announces Positive Results in RADIANCE-HTN TRIO Study and Breakthrough Device Designation for Paradise™ Ultrasound Renal Denervation System

Retrieved on: 
Thursday, December 10, 2020
Interventional radiology, Hypertension, Renal sympathetic denervation, Denervation, Medical specialties, Clinical medicine, Medicine

"ReCor is very pleased with the TRIO outcomes, which demonstrate a clear Paradise treatment effect versus sham," commented President & CEO, Andrew M. Weiss.

Key Points: 
  • "ReCor is very pleased with the TRIO outcomes, which demonstrate a clear Paradise treatment effect versus sham," commented President & CEO, Andrew M. Weiss.
  • "ReCor is pleased that the FDA granted the Breakthrough Designation to the Paradise System," commented Leslie Coleman, Vice President of Regulatory and Medical Affairs at ReCor.
  • ReCor has pioneered the minimally invasive use of ultrasound in renal denervation, and developed the Paradise System, to treat patients with hypertension.
  • For more information about ReCor Medical, please visit www.recormedical.com or contact Andrew M. Weiss, President & CEO, ReCor Medical at [email protected] / +1-650-542-7700.

ReCor Medical Announces Positive Results in RADIANCE-HTN TRIO Study and Breakthrough Device Designation for Paradise™ Ultrasound Renal Denervation System

Retrieved on: 
Thursday, December 10, 2020
Interventional radiology, Renal sympathetic denervation, Clinical medicine, Medicine, Branches of biology, Denervation, Hypertension

PALO ALTO, Calif., Dec. 10, 2020 /PRNewswire/ --ReCor Medical, Inc. ("ReCor"), a wholly-owned subsidiary of Otsuka Medical Devices, announced today that its Paradise Ultrasound Renal Denervation System (the "Paradise System") demonstrated positive results in the RADIANCE-HTN TRIO ("TRIO") study, and, separately, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with uncontrolled hypertension who are inadequately responsive to anti-hypertensive medications.

Key Points: 
  • PALO ALTO, Calif., Dec. 10, 2020 /PRNewswire/ --ReCor Medical, Inc. ("ReCor"), a wholly-owned subsidiary of Otsuka Medical Devices, announced today that its Paradise Ultrasound Renal Denervation System (the "Paradise System") demonstrated positive results in the RADIANCE-HTN TRIO ("TRIO") study, and, separately, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with uncontrolled hypertension who are inadequately responsive to anti-hypertensive medications.
  • "ReCor is very pleased with the TRIO outcomes, which demonstrate a clear Paradise treatment effect versus sham," commented President & CEO, Andrew M. Weiss.
  • "ReCor is pleased that the FDA granted the Breakthrough Designation to the Paradise System," commented Leslie Coleman, Vice President of Regulatory and Medical Affairs at ReCor.
  • ReCor has pioneered the minimally invasive use of ultrasound in renal denervation, and developed the Paradise System, to treat patients with hypertension.

SoniVie Receives FDA Breakthrough Device Designation for the TIVUS System for Renal Artery Denervation

Retrieved on: 
Wednesday, December 9, 2020
Hypertension, Interventional radiology, Medicine, Clinical medicine, Medical specialties, Renal sympathetic denervation, Denervation, Pulmonary hypertension, Radiofrequency ablation

Breakthrough Device Designation is a special regulatory status granted to medical devices that provide a more effective treatment for life-threatening or irreversibly debilitating diseases.

Key Points: 
  • Breakthrough Device Designation is a special regulatory status granted to medical devices that provide a more effective treatment for life-threatening or irreversibly debilitating diseases.
  • The Company previously received Breakthrough Device Designation for the TIVUS System in the treatment of pulmonary arterial hypertension (PAH) in September 2019.
  • Renal denervation with the TIVUS System is a minimally invasive procedure that uses high-frequency non-focused ultrasound to ablate nerves in the renal artery.
  • SoniVie is a medical device company developing the TIVUS Ultrasonic Denervation System, the only platform denervation technology with active development programs in three therapeutic areas: pulmonary artery denervation for pulmonary hypertension, renal artery denervation for resistant hypertension, and total lung denervation for chronic obstructive pulmonary disease with chronic bronchitis.

2020 Insights into the Renal Denervation Catheters Market to 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 8, 2020
Medical devices, Health, Business process, Hypertension, Interventional radiology, Renal sympathetic denervation, Denervation, Market analysis, Database, Medical specialties, Clinical medicine, Medicine

The "Global Renal Denervation Catheters Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Renal Denervation Catheters Market" report has been added to ResearchAndMarkets.com's offering.
  • This report was developed using extensive primary and secondary research by the publisher's analysts.
  • Data from proprietary databases, proprietary market reports, company reports, import/export databases, and secondary data sources on medical device markets were used to develop estimates of 2019 worldwide market size by product segment, ASPs, sales, and market share for the top suppliers by product segment.
  • Devices in this global market analysis include renal denervation catheters.

DGAP-News: Gradient Denervation Technologies Raises €3.5M in Seed Funding with Sofinnova Partners

Retrieved on: 
Thursday, September 17, 2020
Medicine, Clinical medicine, Hypertension, Sofinnova, Medical specialties, Medical terminology, Denervation, Minimally invasive procedure, Pulmonary hypertension, Interventional radiology, Renal sympathetic denervation, Gradient Denervation Technologies, Sofinnova Partners, Sofinnova MD Start III

PARIS, FRANCE / ACCESSWIRE / September 17, 2020 / Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of pulmonary hypertension, announced today the close of a 3.5M seed financing from Sofinnova Partners to support the development of its intravascular, catheter-based technology.

Key Points: 
  • PARIS, FRANCE / ACCESSWIRE / September 17, 2020 / Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive solution for the treatment of pulmonary hypertension, announced today the close of a 3.5M seed financing from Sofinnova Partners to support the development of its intravascular, catheter-based technology.
  • Founded in February 2020, Gradient Denervation Technologies ("Gradient") builds on an innovation from two clinicians from Stanford University, Dr. Swami Gnanashanmugam and Dr. Jeffrey Feinstein.
  • Gradient Denervation Technologies develops a device-based minimally invasive solution for the treatment of pulmonary hypertension with technology developed by two clinicians from Stanford University.
  • It is a privately held portfolio company of Sofinnova Partners, financed through the MD Start III Fund and based in Paris, France.

New Real-World Data from Medtronic Global SYMPLICITY Registry Show Renal Denervation Lowered Blood Pressure in Patients with Hypertension Out to Three Years

Retrieved on: 
Thursday, June 25, 2020
Cardiovascular system, Medicine, Circulatory system, Renal sympathetic denervation, Hypertension, Antihypertensive drug, Orthostatic hypertension, Hypertensive encephalopathy

The number of patients at the very highest BP level greater than 180 mmHg systolic at baseline dropped by two-thirds at three years.

Key Points: 
  • The number of patients at the very highest BP level greater than 180 mmHg systolic at baseline dropped by two-thirds at three years.
  • The BP drops occurred while patients were prescribed an average of four or more anti-hypertensive medications, which remained unchanged over three years.
  • The Global SYMPLICITY Registry is the largest study documenting the long-term safety and effectiveness of the Medtronic renal denervation systems in a real-world setting in patients with uncontrolled hypertension.
  • To date, the registry has enrolled more than 2,860 patients treated with RDN and includes three-year follow-up for more than 2,500 patients.

Landmark SPYRAL HTN-OFF MED Pivotal Trial Shows Superiority for Renal Denervation in Patients with High Blood Pressure Compared to Sham Procedure

Retrieved on: 
Sunday, March 29, 2020
Hypertension, Medicine, Medical specialties, Cardiovascular system, Renal sympathetic denervation, Denervation, Cardiovascular disease, Antihypertensive drug

The prospectively powered study of patients with uncontrolled high blood pressure (BP) not taking anti-hypertensive medications met itsprimary and secondary effectiveness endpoints, with a >99.9% probability of superiority for both versus those who received a sham control procedure.

Key Points: 
  • The prospectively powered study of patients with uncontrolled high blood pressure (BP) not taking anti-hypertensive medications met itsprimary and secondary effectiveness endpoints, with a >99.9% probability of superiority for both versus those who received a sham control procedure.
  • Blood pressure reductions were sustained consistently throughout the day and nighttime periods, which may offer an important benefit as cardiovascular risk is higher during the nighttime period.
  • Medtronic also recently received Breakthrough Device Designation by the FDA for the Symplicity Spyral renal denervation system.
  • The SPYRAL HTN-OFF MED Pivotal Trial is part of the SPYRAL HTN Global Clinical Trial Program and accompanies the SPYRAL HTN-ON MED Trial and the SPYRAL DYSTAL Study.